BR112017000043A2 - inibidores da desmetilase específica de lisina-1 - Google Patents

inibidores da desmetilase específica de lisina-1

Info

Publication number
BR112017000043A2
BR112017000043A2 BR112017000043-1A BR112017000043A BR112017000043A2 BR 112017000043 A2 BR112017000043 A2 BR 112017000043A2 BR 112017000043 A BR112017000043 A BR 112017000043A BR 112017000043 A2 BR112017000043 A2 BR 112017000043A2
Authority
BR
Brazil
Prior art keywords
lysine
specific demethylase
demethylase inhibitors
inhibitors
specific
Prior art date
Application number
BR112017000043-1A
Other languages
English (en)
Portuguese (pt)
Inventor
K. Chen Young
Kanouni Toufike
Nie Zhe
Alan Stafford Jeffrey
Marvin Veal James
Original Assignee
Celgene Quanticel Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.
Publication of BR112017000043A2 publication Critical patent/BR112017000043A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyamides (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112017000043-1A 2014-07-03 2015-06-29 inibidores da desmetilase específica de lisina-1 BR112017000043A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462020886P 2014-07-03 2014-07-03
US62/020,886 2014-07-03
PCT/US2015/038345 WO2016003917A1 (en) 2014-07-03 2015-06-29 Inhibitors of lysine specific demethylase-1

Publications (1)

Publication Number Publication Date
BR112017000043A2 true BR112017000043A2 (pt) 2018-07-17

Family

ID=55019883

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000043-1A BR112017000043A2 (pt) 2014-07-03 2015-06-29 inibidores da desmetilase específica de lisina-1

Country Status (29)

Country Link
US (3) US9902719B2 (enExample)
EP (2) EP3511319B1 (enExample)
JP (2) JP6663866B2 (enExample)
KR (1) KR102475498B1 (enExample)
CN (2) CN108530424B (enExample)
AU (1) AU2015284383B2 (enExample)
BR (1) BR112017000043A2 (enExample)
CA (1) CA2954049A1 (enExample)
CL (1) CL2016003422A1 (enExample)
CO (1) CO2017000549A2 (enExample)
CY (1) CY1125127T1 (enExample)
DK (2) DK3164380T3 (enExample)
EA (2) EA201891526A3 (enExample)
EC (1) ECSP17006821A (enExample)
ES (2) ES2948782T3 (enExample)
FI (1) FI3511319T3 (enExample)
HR (2) HRP20220414T1 (enExample)
HU (2) HUE058852T2 (enExample)
IL (2) IL249881B (enExample)
LT (2) LT3511319T (enExample)
MX (2) MX395534B (enExample)
PL (2) PL3164380T3 (enExample)
PT (2) PT3164380T (enExample)
RS (2) RS64423B1 (enExample)
SA (1) SA517380651B1 (enExample)
SG (2) SG10201802501RA (enExample)
SI (2) SI3511319T1 (enExample)
SM (2) SMT202300205T1 (enExample)
WO (1) WO2016003917A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987876A1 (en) 2015-06-12 2016-12-15 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
US11034991B2 (en) 2016-03-16 2021-06-15 Oryzon Genomics S.A. Methods to determine KDM1A target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
LT3661510T (lt) 2017-08-03 2025-01-27 Oryzon Genomics, S.A. Elgesio pakitimų gydymo būdai
PE20211050A1 (es) * 2018-08-10 2021-06-04 Navire Pharma Inc Inhibidores de ptpn11
CN113365996B (zh) * 2019-02-01 2024-09-03 韩美药品株式会社 咪唑吡啶衍生化合物以及药物组成物
JP7532386B2 (ja) 2019-02-01 2024-08-13 ハンミ ファーマシューティカルズ カンパニー リミテッド イミダゾピリジン誘導体化合物及びその用途
CN120837494A (zh) 2019-03-20 2025-10-28 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
WO2021004610A1 (en) 2019-07-05 2021-01-14 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
US11360505B2 (en) 2020-02-11 2022-06-14 Simmonds Precision Products, Inc. Distributed network time synchronization
CN114105950B (zh) * 2020-08-31 2022-09-06 南京明德新药研发有限公司 吡唑类化合物及其应用
EP4306520A4 (en) * 2021-03-11 2025-05-07 Medshine Discovery Inc. THIOPHENE COMPOUND AND ITS USE
CN117062813A (zh) * 2021-03-24 2023-11-14 四川汇宇制药股份有限公司 一种多环化合物及其应用
KR20230167102A (ko) 2021-04-08 2023-12-07 오리존 지노믹스 에스.에이. 골수성 암 치료를 위한 lsd1 억제제의 조합물
CN116102533A (zh) * 2021-11-11 2023-05-12 中国科学院上海药物研究所 一种芳杂环类化合物及其应用
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
JP2025516648A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Lsd1阻害薬を用いるnf1変異腫瘍の治療法
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963188A1 (de) 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
WO2002026718A2 (en) * 2000-09-29 2002-04-04 Millennium Pharmaceutical, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
US7365069B2 (en) * 2002-04-10 2008-04-29 Bexel Pharmaceuticals Inc. Pyrimidone derivatives
JP2005170792A (ja) * 2002-11-22 2005-06-30 Mitsubishi Pharma Corp L−プロリン誘導体およびその医薬としての用途。
US7504423B2 (en) 2003-12-11 2009-03-17 Mitsubishi Tanabe Pharma Corporation α-amino acid derivatives and use thereof as medicines
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
PL372332A1 (pl) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
WO2006129181A2 (en) * 2005-06-03 2006-12-07 Orchid Research Laboratories Limited Preparation of 4-pyrimidone derivatives for treating inflammatory diseases
EP1924561B1 (en) 2005-09-01 2012-11-14 Eli Lilly & Company 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
JP2007197324A (ja) * 2006-01-23 2007-08-09 Toray Ind Inc 2,4,5−置換−1,3−アゾール誘導体
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
PE20081803A1 (es) 2007-03-09 2008-12-11 Wyeth Corp Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
US20130096160A1 (en) 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
EP2822946A1 (en) * 2012-03-06 2015-01-14 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
JP6430512B2 (ja) * 2013-12-11 2018-11-28 セルジーン クオンティセル リサーチ,インク. リジン特異的デメチラーゼ−1の阻害剤
KR20160115999A (ko) * 2014-02-14 2016-10-06 더 유니버시티 오브 브리티쉬 콜롬비아 치료제로서의 인간 안드로겐 수용체 dna-결합 도메인(dbd) 화합물 및 그의 사용 방법
SI3137169T1 (sl) * 2014-05-01 2022-04-29 Celgene Quanticel Research, Inc. Inhibitorji lizin specifične demetilaze-1
FR3020945B1 (fr) 2014-05-16 2016-05-06 Oreal Composition pour colorer les fibres keratiniques comprenant une base d'oxydation et un coupleur heteroaryle particulier
LT3160956T (lt) * 2014-06-27 2020-09-10 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai
US10414750B2 (en) * 2014-07-03 2019-09-17 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1

Also Published As

Publication number Publication date
PT3511319T (pt) 2023-06-29
SI3164380T1 (sl) 2022-06-30
EA201891526A2 (ru) 2018-12-28
AU2015284383B2 (en) 2019-04-18
KR102475498B1 (ko) 2022-12-07
LT3164380T (lt) 2022-06-27
CN106795103A (zh) 2017-05-31
IL272130B (en) 2021-03-25
IL272130A (en) 2020-03-31
DK3511319T3 (da) 2023-07-31
HRP20230595T1 (hr) 2023-09-15
LT3511319T (lt) 2023-08-25
IL249881B (en) 2020-01-30
US10100046B2 (en) 2018-10-16
ECSP17006821A (es) 2017-03-31
DK3164380T3 (da) 2022-03-28
JP2017525668A (ja) 2017-09-07
HUE058852T2 (hu) 2022-09-28
EA033698B1 (ru) 2019-11-18
ES2948782T3 (es) 2023-09-19
MX2020010900A (es) 2022-09-13
SG11201610975RA (en) 2017-01-27
SMT202200136T1 (it) 2022-05-12
PL3511319T3 (pl) 2023-09-11
EP3164380A4 (en) 2018-07-18
CO2017000549A2 (es) 2017-04-20
JP6663866B2 (ja) 2020-03-13
RS64423B1 (sr) 2023-09-29
US20170129882A1 (en) 2017-05-11
FI3511319T3 (fi) 2023-07-20
SMT202300205T1 (it) 2023-09-06
EP3164380A1 (en) 2017-05-10
US9902719B2 (en) 2018-02-27
EP3511319B1 (en) 2023-05-03
HRP20220414T1 (hr) 2022-05-27
EP3164380B1 (en) 2022-02-09
MX376207B (es) 2025-03-07
ES2907676T3 (es) 2022-04-26
CN108530424A (zh) 2018-09-14
MX395534B (es) 2025-03-25
US20190002456A1 (en) 2019-01-03
US20180127408A1 (en) 2018-05-10
CN106795103B (zh) 2019-07-12
CN108530424B (zh) 2021-10-01
EP3511319A1 (en) 2019-07-17
CL2016003422A1 (es) 2017-11-10
EA201891526A3 (ru) 2019-05-31
PL3164380T3 (pl) 2022-04-04
HUE062558T2 (hu) 2023-11-28
RS63074B1 (sr) 2022-04-29
CA2954049A1 (en) 2016-01-07
AU2015284383A1 (en) 2017-02-02
SA517380651B1 (ar) 2020-09-30
MX2017000168A (es) 2017-05-01
KR20170018100A (ko) 2017-02-15
CY1125127T1 (el) 2024-02-16
SI3511319T1 (sl) 2023-10-30
PT3164380T (pt) 2022-03-02
IL249881A0 (en) 2017-03-30
SG10201802501RA (en) 2018-05-30
EA201790085A1 (ru) 2017-08-31
WO2016003917A1 (en) 2016-01-07
JP6768857B2 (ja) 2020-10-14
JP2019108346A (ja) 2019-07-04

Similar Documents

Publication Publication Date Title
IL263586A (en) Inhibitors of the menin-mll interaction
BR112017000043A2 (pt) inibidores da desmetilase específica de lisina-1
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
BR112017004334A2 (pt) inibidores de desmetilase específica de lisina-1.
CL2016002736A1 (es) Inhibidores de demetilasa-1 específico de lisina
LT3303334T (lt) Tirozinkinazės inhibitoriai
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
MA53944A (fr) Inhibiteurs de la glycosidase
PT3105226T (pt) Ciclopropilaminas como inibidores de lsd1
DK3442972T3 (da) Bromdomænehæmmere
BR112016030367A2 (pt) inibidores de histona desmetilase
BR112016030697A2 (pt) inibidores da desmetilase-1 específica da lisina
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3191487T3 (da) Spirocykliske cathepsin-c-inhibitorer
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3341379T3 (da) EZH2-hæmmere
BR112017005128A2 (pt) inibidores de histona desmetilase
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
BR112017005511A2 (pt) inibidores da histona-desmetilase.
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
EP3519429A4 (en) BACTERIAL INHIBITORS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07C 255/49

Ipc: C07D 401/04 (1974.07), C07D 401/14 (1974.07), C07D

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements